Annual report [Section 13 and 15(d), not S-K Item 405]

Acquisitions - Summary of Purchase Price Allocation (Details)

v3.25.4
Acquisitions - Summary of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 16, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Liabilities assumed:        
Total liabilities assumed $ 49,610      
Goodwill   $ 88,210 $ 15,540 $ 13,328
Keystone Perfusion Services, LLC.        
Business Combination [Line Items]        
Cash paid directly to seller 66,985      
Equity consideration 8,414      
Equity consideration in escrow and Contingent considerations 23,000 4,625    
Total purchase consideration 84,513      
Assets acquired:        
Cash 450      
Accounts receivable 10,611      
Prepaid expenses and other current assets 3,686      
Property and equipment, net 4,996      
Identifiable intangible assets 41,700      
Other non-current assets 10      
Total identifiable assets acquired 61,453      
Liabilities assumed:        
Acquiree liabilities settled by the buyer in cash on close date 44,339      
Accounts payable and accrued expenses 4,630      
Deferred revenue 641      
Net assets acquired 11,843      
Goodwill 72,670      
Total consideration 84,513      
Post-close net working capital and gross-up adjustment   1,361    
Contingent consideration earn out receivable   $ 3,967    
Keystone Perfusion Services, LLC. | Equity consideration in escrow        
Business Combination [Line Items]        
Equity consideration in escrow and Contingent considerations 8,414      
Keystone Perfusion Services, LLC. | Contingent earn-out consideration        
Business Combination [Line Items]        
Equity consideration in escrow and Contingent considerations 700      
Keystone Perfusion Services, LLC. | Contingent Earn-Out Consideration        
Business Combination [Line Items]        
Equity consideration in escrow and Contingent considerations 3,425      
Liabilities assumed:        
Contingent consideration earn out receivable $ 2,725